Skip to content

European Neuropsychopharmacology

ISSN 0924-977X, 1873-7862

108 papers in the library · 2,652 citations · publishing 1995-2026

Papers

Sort Most recent Most cited

A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood.

European Neuropsychopharmacology May 2024 Brooke Manning, Amie C Hayley, Sarah J Catchlove et al.

As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg...

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

European Neuropsychopharmacology March 1, 2024 Marcelo Falchi-Carvalho, Isabel Wießner, Sérgio Ruschi B Silva et al. 25 citations

Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) last over several hours, inhaled N,N-Dimethyltryptamine (DMT) effects last around 10 min, which might provide a cost- and time-effective alternative to the clinical application of oral psychedelics. We aimed at...

DOI: 10.1016/j.euroneuro.2023.12.006 (opens in new tab) Full text (opens in new tab) Entheogens Clinical trial Dose-response study Mood disorders +6

The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.

European Neuropsychopharmacology November 1, 2023 Michael James Winkelman, Attila Szabo, Ede Frecska 26 citations

Alzheimer's Disease (AD) is a currently incurable but increasingly prevalent fatal and progressive neurodegenerative disease, demanding consideration of therapeutically relevant natural products and their synthetic analogues. This paper reviews evidence for effectiveness of natural and synthetic psychedelics in the treatment of AD causes and symptoms. The plastogenic effects of serotonergic...

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

European Neuropsychopharmacology August 7, 2023 Natacha Perez, Florent Langlest, Luc Mallet et al. 85 citations

Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...

Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms

European Neuropsychopharmacology June 21, 2023 Seline Mock, Nicole Friedli, Patrick Pasi et al. 46 citations

Eating disorders are serious illnesses showing high rates of mortality and comorbidity with other mental health problems. Psychedelic-assisted therapy has recently shown potential in the treatment of several common comorbidities of eating disorders, including mood disorders, post-traumatic stress disorder, and substance use disorders. The theorized therapeutic mechanisms of psychedelic-assisted...

DOI: 10.1016/j.euroneuro.2023.05.008 (opens in new tab) Anxiety Anorexia nervosa Bulimia nervosa Eating disorders +7

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study

European Neuropsychopharmacology May 4, 2023 Stefania Chiappini, Giacomo D’andrea, Sergio De Filippis et al. 48 citations

Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of psychiatric emergency due to major depressive disorder (MDD) and for depressive symptoms in adults with MDD with acute suicidal...

Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?

European Neuropsychopharmacology May 2023 Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo et al.

Ketamine and esketamine, the S-enantiomer of the racemic mixture, have recently generated considerable interest as potential therapeutic agents for Treatment-Resistant Depression (TRD), a complex disorder that includes various psychopathological dimensions and distinct clinical profiles (e.g., comorbid personality disorder, bipolar spectrum, dysthymic disorder). This perspective article...

DOI: 10.1016/j.euroneuro.2023.02.010 (opens in new tab) Full text (opens in new tab) Esketamine Bipolar depression Mood stabilizers Rapid-acting therapies +1

LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals.

European Neuropsychopharmacology March 1, 2023 Isabel Wießner, Marcelo Falchi, Dimitri Daldegan-Bueno et al. 6 citations

Language has been explored as a window into the mind. Psychedelics, known to affect perception and cognition, seem to change language, but a systematic, time-dependent exploration is lacking. Therefore, we aimed at mapping the psychedelic effects on language over the time course of the acute and sub-acute effects in an explorative manner. For this, 24 healthy volunteers (age [mean±SD, range]:...

Effects of ketamine optical isomers, fluoxetine and naloxone on timing in differential reinforcement of low-rate response (DRL) 72-s task in rats.

European Neuropsychopharmacology February 2023 Natalia Malikowska‐racia, Joanna Gołębiowska, Agnieszka Nikiforuk et al.

(S)-ketamine-induced rapid-acting antidepressant effects have revolutionized the pharmacotherapy of major depression; however, this medication also produces psychotomimetic effects such as timing distortion. While (R)-ketamine produces fewer dissociative effects, its antidepressant actions are less studied. Depression is associated with time overestimation (i.e., subjectively, time passes...

Ayahuasca's therapeutic potential: What we know - and what not.

European Neuropsychopharmacology 2023 Lucas Oliveira Maia, Dimitri Daldegan-Bueno, Isabel Wießner et al. 46 citations

The therapeutic potential of the psychedelic brew ayahuasca has been investigated in preclinical and clinical studies. Currently, the most consistent evidence refers to depression. However, various studies suggest that ayahuasca may comprise therapeutic benefits in other health conditions. This narrative review provides a comprehensive, up-to-date overview of ayahuasca's therapeutic effects in...

Single dose S-ketamine rescues transcriptional dysregulation of Mtor and Nrp2 in the prefrontal cortex of FSL rats 1hour but not 14 days post dosing.

European Neuropsychopharmacology November 11, 2022 Betina Elfving, Nico Liebenberg, Kristian Du Jardin et al.

There is a pressing need to identify biological indicators of major depression to help guide proper diagnosis and optimize treatment. Animal models mimicking aspects of depression constitute essential tools for early-stage exploration of relevant pathways. In this study, we used the Flinders Sensitive and Resistant Line (FSL/FRL) to explore central and peripheral transcriptional changes in...

A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs.

European Neuropsychopharmacology November 1, 2022 Marco Solmi, Chaomei Chen, Charles Dauré et al. 55 citations

A scientometric analysis was realized to outline clinical research on psychedelics over the last century. Web of Science Core Collection was searched up to March 18, 2022, for publications on psychedelics. Network analyses and bibliometrics were combined, to identify research themes and trends with Bibliometrix and CiteSpace. The primary aim was to measure research trends evolution over time,...

DOI: 10.1016/j.euroneuro.2022.09.004 (opens in new tab) Full text (opens in new tab) Bibliometrix Citespace Evidence synthesis Mood disorders +6

Invisible wounds: Suturing the gap between the neurobiology, conventional and emerging therapies for posttraumatic stress disorder.

European Neuropsychopharmacology August 2022 Xénia Gonda, Péter Döme, Berta Erdelyi-Hamza et al.

A sharp increase in the prevalence of neuropsychiatric disorders, including major depression, anxiety, substance use disorders and posttraumatic stress disorder (PTSD) has occurred due to the traumatic nature of the persisting COVID-19 global pandemic. PTSD is estimated to occur in up to 25% of individuals following exposure to acute or chronic trauma, and the pandemic has inflicted both forms...

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility.

European Neuropsychopharmacology May 1, 2022 Isabel Wießner, Rodolfo Olivieri, Marcelo Falchi et al. 42 citations

Psychedelics acutely impair cognitive functions, but these impairments decline with growing experiences with psychedelics and microdoses may even exert opposing effects. Given the recent evidence that psychedelics induce neuroplasticity, this explorative study aimed at investigating the potential of psychedelics to sub-acutely change cognition. For this, we applied a randomized, double-blind,...

DOI: 10.1016/j.euroneuro.2022.01.114 (opens in new tab) Full text (opens in new tab) Cognitive flexibility Executive functions Phonological verbal fluency Psycholytic dose +2

Pharmacological characterization of 3,4-methylenedioxyamphetamine (MDA) analogs and two amphetamine-based compounds: ,α-DEPEA and DPIA

European Neuropsychopharmacology April 1, 2022 Karolina E. Kolaczynska, Paula Ducret, Daniel Trachsel et al. 7 citations

3,4-methylenedioxyamphetamine (MDA) is a psychoactive compound chemically related to the entactogen MDMA. MDA shares some of the entactogenic effects of MDMA but also exerts stimulant effects and psychedelic properties at higher doses. Here, we examined the pharmacological properties of MDA analogs and related amphetamine-based compounds detected in street drug samples or in sport supplements....

DOI: 10.1016/j.euroneuro.2022.03.006 (opens in new tab) MDMA Serotonin Pharmacology Monoamine neurotransmitter +5

Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure

European Neuropsychopharmacology February 3, 2022 Lilian Kloft, Henry Otgaar, Arjan Blokland et al. 17 citations

The entactogen 3,4-Methylenedioxymethamphetamine (MDMA) is increasingly being recognized for its therapeutic potential but is also widespread in nightlife settings where it may co-occur with crime. Since previous research detected impaired verbal memory during acute MDMA intoxication, understanding the drug's ramifications in an applied legal context becomes crucial. We conducted a...

Guanosine boosts the fast, but not sustained, antidepressant-like and pro-synaptogenic effects of ketamine by stimulating mTORC1-driven signaling pathway.

European Neuropsychopharmacology January 7, 2022 A. Camargo, A. P. Dalmagro, Eslen Delanogare et al.

The mTORC1-dependent dendritic spines formation represents a key mechanism for fast and long-lasting antidepressant responses, but it remains to be determined whether this mechanism may account for the ability of guanosine in potentiating ketamine's actions. Here, we investigated the ability of ketamine plus guanosine to elicit fast and sustained antidepressant-like and pro-synaptogenic effects...

P.0623 The clinical relevance of the pharmacokinetics of psilocybin

European Neuropsychopharmacology December 1, 2021 A. Andreiev, E. Bucuci, James Chue et al. 1 citation

Nicotine dependence is a reversible risk factor of numerous oral cavity diseases. Dentist should be non-smoking and have knowledge on diagnosis and treatment of nicotine addiction.The aim of this survey is the assessment of prevalence of nicotine dependence among Polish dentists, factors associated with this addiction and knowledge on minimal anti-nicotine intervention acquired during pre- and...

P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression – a comprehensive literature review

European Neuropsychopharmacology December 1, 2021 S. Penedos, C. Ramos, M. Miguel et al. 1 citation

Introduction: Psychedelics have seen various labels: mystical sacrament aids, potential interrogation tools for the Cold War, agents for social change in the Hippie counter movement, a panacea for various mental disorders, and a tool to “hack” of the psyche. This has led to their reputation as both societal threat and a psychopharmacological breakthrough. After the loss of data on over 1000...

Frequent Δ9- tetrahydrocannabinol exposure during adolescence impairs sociability in adult mice exposed to an aversive painful stimulus.

European Neuropsychopharmacology December 2021 Alex Mabou Tagne, Yannick Fotio, Zachary Alan Springs et al.

Early-life exposure to Δ9-tetrahydrocannabinol (Δ9-THC), the intoxicating constituent of cannabis, may produce enduring neurochemical changes in brain structures involved in the regulation of sociality but it is still unclear how such changes influence social behavior later in life. In the present study, we exposed male mice to moderate daily doses of Δ9-THC (5 mg/kg, intraperitoneal) during...

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience.

European Neuropsychopharmacology September 1, 2021 Martin K Madsen, Dea S Stenbæk, Albin Arvidsson et al. 132 citations

The emerging novel therapeutic psilocybin produces psychedelic effects via engagement of cerebral serotonergic targets by psilocin (active metabolite). The serotonin 2A receptor critically mediates these effects by altering distributed neural processes that manifest as increased entropy, reduced functional connectivity (FC) within discrete brain networks (i.e., reduced integrity) and increased...

The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: results from a randomized double-blind study

European Neuropsychopharmacology June 2, 2021 A. Feeney, Rebecca S. Hock, Marlene P. Freeman et al. 33 citations

This study aimed to assess the effect of a single infusion of intravenous (IV) ketamine on suicidal ideation in patients with treatment-resistant depression (TRD). Patients with TRD were randomized in a double-blind fashion to a single infusion of IV ketamine or IV midazolam placebo. Suicidal ideation was measured using the Montgomery-Asberg Depression Rating Scale (MADRS) suicide item at 3, 5,...

Psychonauts’ psychedelics: A systematic, multilingual, web-crawling exercise

European Neuropsychopharmacology April 13, 2021 Valeria Catalani, John Corkery, Amira Guirguis et al. 18 citations

Psychedelics alter the perception of reality through agonist or partial agonist interaction with the 2A serotoninergic receptor. They are classified as phenethylamines, tryptamines and lysergamides. These classes, according to the United Nations Office on Drugs and Crime (UNODC) and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), account for an important percentage of the new...

DOI: 10.1016/j.euroneuro.2021.03.006 (opens in new tab) Phenethylamines Pergolide Crawling Hallucinogen +4

Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers.

European Neuropsychopharmacology March 2021 Torsten Passie, Hans-Anton Adams, Frank Logemann et al.

Ketamine and its (S)-enantiomer show distinct psychological effects that are investigated in psychiatric research. Its antidepressant activity may depend on the extent and quality of these psychological effects which may greatly differ between the enantiomers. Previous data indicate that the (S)-ketamine isomer is a more potent anesthetic than (R)-ketamine. In contrast, in subanesthetic doses...